The company trades in gold and diamond-studded jewelry and provides marketing consultancy services to the pharmaceutical industry in India.
The company operates as a small-scale commodity trader in highly fragmented markets with no evidence of brand power or cost advantages, as reflected by a low 2.3% average ROCE. The shift from jewelry to pharmaceutical consultancy appears opportunistic rather than structural, lacking any proprietary intellectual property or network effects.
Capital has been deployed into small equity stakes in unrelated private ventures, including automotive and biotech firms, which have yet to yield meaningful returns. The company relies on preferential allotments to fund operations and has a history of carrying high-interest loans from former directors despite holding significant cash balances.
The company's pivot from jewelry to pharmaceutical consultancy proved to be a hollow shell, as the lack of proprietary IP or scale advantages led to terminal revenue erosion. Capital was permanently impaired through speculative investments in unrelated private ventures like Ferry Automotive, which failed to generate liquidity. The breakdown in internal controls, evidenced by the auditor's inability to access internal reports, eventually masked a liquidity crisis that forced the company to continue diluting shareholders through preferential allotments just to service high-interest debt to former insiders.
RichFakir rates Deep Health AI India Ltd's business quality as poor — 20/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as none.
On our model, Deep Health AI India Ltd is trading far above our estimate of fair value (expensive on our lens); we rate its price expensive. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Deep Health AI India Ltd is: Avoid. We are steering clear of this one — the red flags below outweigh anything the price or numbers offer.
RichFakir's educational estimate of Deep Health AI India Ltd's fair value is about ₹1 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →